Skip to main content

Advertisement

SpringerLink
Log in

Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Leiomyosarcoma (LMS) is an aggressive, malignant mesenchymal tumor with characteristic smooth muscle lineage accounting for 10–20% of all soft tissue tumors. The goal of this study is to determine the impact of prognostic factors on leiomyosarcoma survival irrespective of primary anatomical site.

Methods

There were a total of 7154 patients with primary leiomyosarcoma identified and analyzed from the National Cancer Database. Descriptive statistics, median survival, and 5- and 10-year survival probabilities were calculated along with a Cox proportional hazard model to determine independent prognostic factors.

Results

In this study, females comprised 68.3% of the cohort with a median age of 58 years. The most common primary anatomical sites were the extremities followed by female reproductive organs, abdomen, pelvis, thorax or lung, and head or neck. Tumors localized in the female reproductive organs had the worst survival (5-year survival probability: 45.3%), while tumors localized in the extremities had the best survival outcomes (5-year survival probability: 73.4%). Surgery with adjuvant radiation yielded better outcomes compared to surgery alone (HR 0.82, 95% CI 0.74–0.91). Microscopic and macroscopic margins resulted in a 32% and a 134% increased risk in mortality, respectively, when compared to negative surgical margins (p < 0.0001).

Conclusion

This study showed a significantly higher risk of mortality associated with older patients, tumors localized to the female reproductive organs, African American patients, higher tumor stage, increased Charlson/Deyo scores, tumors treated with surgery alone without adjuvant radiation, and tumors with positive microscopic, macroscopic, or indeterminate surgical margins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin N Am. 2013;27(5):957–74.

    Article  Google Scholar 

  2. Wang Z, Shi N, Naing A, et al. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016;5(12):3437–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dodd, Leslie G (2014) Atlas of soft tissue and bone pathology: with histologic, cytologic, and radiologic correlations

  4. Nusrath S, Vipin G, Narasimha R, Subramanyeshwar R, Sudha M. Primary pulmonary leiomyosarcoma: a case report. Indian J Thorac Cardiovasc Surg. 2018;34:76–9.

    Article  Google Scholar 

  5. Alfarelos G, Campos M, Canelas A, Gonçalves M. Paratesticular leiomyosarcoma: a case report and review of the literature. Urol Case Rep. 2017;11.C:30–2.

    Article  Google Scholar 

  6. Bathan A, Constantinidou A, Pollack S, Jones R. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013;24(4):384–9.

    Article  Google Scholar 

  7. Rubenzik M, et al. Leiomyosarcoma. Mohs micrographic surgery. 2012nd ed. London: Springer; 2012. p. 279–285.

    Book  Google Scholar 

  8. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology. 2006;48(1):97–105.

    Article  CAS  PubMed  Google Scholar 

  9. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–89.

    Article  CAS  PubMed  Google Scholar 

  10. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914–26.

    Article  CAS  PubMed  Google Scholar 

  11. Weiss SW. Smooth muscle tumors of soft tissue. Adv Anat Pathol. 2002;9:351–9.

    Article  PubMed  Google Scholar 

  12. Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42.

    Article  PubMed  Google Scholar 

  13. Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol. 2017;145(1):208–16.

    Article  PubMed  Google Scholar 

  14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.

    Article  CAS  PubMed  Google Scholar 

  15. Seagle BL, Sobecki-Rausch J, Strohl AE, et al. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145(1):61–70.

    Article  PubMed  Google Scholar 

  16. Goldblum J, Enzinger F, Folpe A, Weiss S. Enzinger and Weiss's soft tissue tumors. 6th ed. Philadelphia: Saunders; 2014.

    Google Scholar 

  17. Kim H, Cho Y, Kim S, et al. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Int J Clin Oncol. 2015;20(6):1226–322.

    Article  CAS  PubMed  Google Scholar 

  18. Gladdy RA, Qin LX, Moraco N, et al. Predictors of survival and recurrence in primary leiomyosarcoma. Ann Surg Oncol. 2013;20(6):1851–7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lusby K, Savannah K, Demicco B, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution’s experience. Ann Surg Oncol. 2013;20(7):2364–72.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Eppsteiner RW, DeYoung BR, Milhem MM, Pagedar NA. Leiomyosarcoma of the head and neck: a population-based analysis. Arch Otolaryngol Head Neck Surg. 2011;137(9):921–4.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Unal O, Oztop I, Yasar N, Urakci Z, et al. Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Thorac Oncol. 2015;6(1):85–90.

    Google Scholar 

  22. Pautier P, Genestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000;88:1425–31.

    Article  CAS  PubMed  Google Scholar 

  23. Wong ML, Mcmurry TL, Schumacher JR, Hu CY, et al. Comorbidity assessment in the National Cancer Database for patients with surgically resected breast, colorectal, or lung cancer (AFT-01, -02, -03). J Oncol Pract. 2018;14(10):E631–e643643.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.

    Article  CAS  PubMed  Google Scholar 

  25. Brennan M, Antonescu C, Maki R. Management of soft tissue sarcoma. New York: Springer; 2016.

    Book  Google Scholar 

  26. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562–72.

    Article  PubMed  Google Scholar 

  27. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199(5):536.e1–.e8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Creighton University School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA

    J. Gootee, N. Sioda & C. Curtin

  2. Division of Clinical Research and Evaluative Sciences, Creighton University School of Medicine, Omaha, NE, USA

    S. Aurit

  3. Division of Hematology/Oncology, Department of Internal Medicine, Creighton University Medical Center, Omaha, NE, USA

    P. Silberstein

Authors
  1. J. Gootee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Sioda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Aurit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Curtin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Silberstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Gootee.

Ethics declarations

Conflict of interest

This manuscript had no funding sources and the authors declare no conflict of interest.

Ethical approval

Need for ethical approval was waived by the Creighton University Biomedical IRB.

Informed consent

Informed consent was not required as the data was derived from a de-identified file.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gootee, J., Sioda, N., Aurit, S. et al. Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis. Clin Transl Oncol 22, 860–869 (2020). https://doi.org/10.1007/s12094-019-02196-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02196-7

Keywords

Search

Navigation